Patents Examined by Joseph G Dauner
-
Patent number: 11920187Abstract: Provided herein is the identification of markers associated with THCV, THCVA, CBDV, CBDVA, CBGV, or CBGVA production in Cannabis plants and their use in selecting Cannabis plants having modified THCV, THCVA, CBDV, CBDVA, CBGV, or CBGVA activity. The markers are useful for breeding plants having modified varin activity, including elevated THCV levels, by obtaining nucleic acids, detecting one or more markers that indicate modified varin activity, and establishing plant lines having such characteristics.Type: GrantFiled: August 24, 2022Date of Patent: March 5, 2024Assignee: Phylos Bioscience, Inc.Inventors: Erica Bakker, Alisha Holloway, Kayla Hardwick
-
Patent number: 11920183Abstract: The present disclosure provides methods and systems for generating and processing optically tagged beads. A nucleic acid probe comprising a fluorescent tag may be hybridized to a bead to generate an optically tagged bead. The nucleic acid probe hybridized to the optically tagged bead may be detectable by one or more signals and may be substantially unreactive to one or more chemical reactions performed with, or in the presence of, the optically tagged bead.Type: GrantFiled: March 10, 2020Date of Patent: March 5, 2024Assignee: 10X GENOMICS, INC.Inventors: Rajiv Bharadwaj, Zachary Bent
-
Patent number: 11920201Abstract: Provided herein are methods of determining one or more modification(s) of the nucleic acid sequence of at least one nucleic acid and at least one epigenetic alteration of the at least one nucleic acid in a sample of a subject. The sample is derived from a body fluid of the subject. The methods link the one or more modification(s) to a specific cell type.Type: GrantFiled: January 23, 2018Date of Patent: March 5, 2024Assignee: Siemens Healthcare GMBHInventors: Carsten Dietrich, Andreas Emanuel Posch
-
Patent number: 11891653Abstract: Provided herein is a DNA analysis method comprising partitioning a sample into at least a first subsample and a second subsample, wherein the first subsample comprises DNA (e.g., cell-free DNA) with a cytosine modification in a greater proportion; the first subsample undergoes a procedure that affects a first nucleobase in the DNA differently from a second nucleobase in the DNA of the first subsample; and DNA is sequenced to distinguish the first nucleobase from the second nucleobase. Also provided is a combination comprising first and second populations of captured DNA, wherein the first population comprises or was derived from DNA with a cytosine modification in a greater proportion than the second population, and wherein the first population comprises a form of a first nucleobase originally present in the DNA with altered base pairing specificity and a second nucleobase without altered base pairing specificity.Type: GrantFiled: September 30, 2020Date of Patent: February 6, 2024Assignee: Guardant Health, Inc.Inventors: Stefanie Ann Ward Mortimer, William J. Greenleaf
-
Patent number: 11884961Abstract: Provided herein are DNA-glycan conjugates that include a glycan and a covalently attached polynucleotide. The polynucleotide includes a plurality of modules. Each module includes a nucleotide string, and the plurality of modules includes a monomer module that corresponds to each carbohydrate monomer present in the DNA-glycan conjugate, and a linkage module that corresponds to each glycosidic linkage present between each carbohydrate monomer in the DNA-glycan conjugate. The nucleotide sequence of the plurality of modules corresponds to the glycan structure. Also provided herein are methods for making and using the DNA-glycan conjugates. Further provided is a computer-implemented method for translating data from a nucleotide sequence to a glycan structure, a system for converting data from a glycan structure to a nucleotide sequence, and a system for translating data from a nucleotide sequence to a glycan structure.Type: GrantFiled: June 1, 2018Date of Patent: January 30, 2024Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Peng George Wang, Jing Song, Muhammed Shukkoor Kondengaden, Aishwarya Parameswaran
-
Patent number: 11873312Abstract: Compositions and methods of capturing one or more nucleic acid molecules of a cell or subcellular compartment are described. In certain aspects, the compositions comprise a caged molecule comprising one or more photolinkers and an antisense oligonucleotide, which when uncaged hybridizes to a target nucleic acid molecule.Type: GrantFiled: May 28, 2021Date of Patent: January 16, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: James Eberwine, Ivan J. Dmochowski, Sean B. Yeldell, Julianne C. Griepenburg, Teresa L. Rapp, Jennifer M. Singh, Jai-Yoon Sul, Jaehee Lee
-
Patent number: 11866776Abstract: The present application relates to methods for determining the proportion or quantity of DNA contributed by individual animals to a volume of milk collected from a plurality of individual animals, wherein the method employs allele sampling for DNA sequence polymorphisms in DNA extracted from a sample of the volume of milk by shallow whole genome sequencing (SWGS). The present methods are useful for example in detecting mastitis or subclinical mastitis in animals contributing milk to the volume of milk.Type: GrantFiled: March 26, 2019Date of Patent: January 9, 2024Assignee: GESVAL S.A.Inventors: Michel Georges, Wouter Coppieters, Latifa Karim
-
Patent number: 11859239Abstract: Provided is a nucleic acid sample-contained container including; a first nucleic acid molecule including an intended base sequence and a base sequence for detection different from the intended base sequence; and a second nucleic acid molecule free of the intended base sequence but including the base sequence for detection, wherein the nucleic acid sample-contained container includes the first nucleic acid molecule in a predetermined number. In a preferable mode, the copy number of the intended base sequence is less than 1,000, and the coefficient of variation (CV value) for the copy number is lower than 20%. In a more preferable mode, the nucleic acid molecules are artificially synthesized nucleic acid molecules. In a yet more preferable mode, the first nucleic acid molecule includes the intended base sequence in a plural number in the same molecule.Type: GrantFiled: March 18, 2019Date of Patent: January 2, 2024Assignee: Ricoh Company, Ltd.Inventors: Yudai Kawashima, Masayuki Yumoto, Satoshi Izumi, Manabu Seo
-
Patent number: 11851705Abstract: Provided is a method for a two-step multiplex DNA amplification reaction which allows bacterial or fungal DNA analysis without first extracting DNA from the sample, nor without need to enrich microbes by laboratory culture prior to analysis. Without additional DNA purification or analysis, the PCR amplified DNA is administered directly to a microarray designed to interrogate a large panel of meaningful bacteria or fungi as a single multiplex test. Microarray analysis is then performed at ambient temperature, thus enabling substantial simplification of the testing process. It is contemplated that analysis may be conducted on unprocessed and processed leaf wash and similar surface sampling of plant material, cannabis, vegetables, fruit, nuts, spices, grains, other agriculture samples, food samples, or water samples, so as to detect bacterial, yeast, mold or viral, plant or human pathogen contamination.Type: GrantFiled: March 16, 2020Date of Patent: December 26, 2023Assignee: PathogenDX IncInventors: Michael Edward Hogan, Melissa Rose May, Frederick Henry Eggers
-
Patent number: 11845979Abstract: Provided herein are methods, compositions, and kits for the detection of immune cell clonotypes and immune cell analytes within a biological sample.Type: GrantFiled: May 10, 2023Date of Patent: December 19, 2023Assignee: 10x Genomics, Inc.Inventors: Camilla Engblom, Kim Thrane, Jeffrey Mold, Jonas Frisen, Joakim Lundeberg, Qirong Lin
-
Patent number: 11845986Abstract: This disclosure provides methods and compositions for removing one or more high abundance species from a plurality of nucleic acid molecules. In some embodiments, the methods and compositions can be used for normalizing nucleic acid libraries. In some embodiments, molecular labels are used in conjunction with the methods and compositions disclosed herein to improve sequencing efficiency.Type: GrantFiled: April 3, 2019Date of Patent: December 19, 2023Assignee: Becton, Dickinson and CompanyInventors: Eleen Shum, Glenn Fu, Craig Betts
-
Patent number: 11845928Abstract: A method of DNA fragmentation is provided. The method comprising incubating a semi-solid biological sample which comprises the DNA with an auxiliary domain-directed nuclease having a binding affinity and selectivity to pre-defined sites in the DNA so as to yield a DNA fragment-of-interest, to thereby fragment the DNA.Type: GrantFiled: April 14, 2016Date of Patent: December 19, 2023Assignee: Tsinghua UniversityInventors: Ting Zhu, Yuval Ebenstein, Chunbo Lou, Wenjun Jiang, Xuejin Zhao, Tslil Gabrieli
-
Patent number: 11834717Abstract: The present invention relates to a method for predicting clinical outcome for a subject diagnosed with colorectal cancer, skin cancer, head and neck cancer or lung cancer. It also relates to a method for predicting whether a subject has a predisposition to develop such cancers as well as to a method for aiding the staging of such cancers in a subject. The methods of the present invention apply to the biomarkers MYO5B and/or RAB8A and optionally in addition to RAB9A, RAB10, RAB11A, RAB25, CDC42, RAC and/or RhoA.Type: GrantFiled: August 10, 2018Date of Patent: December 5, 2023Assignee: Universite du LuxembourgInventors: Elisabeth Letellier, Martine Schmitz, Aurelien Ginolhac, Serge Haan
-
Patent number: 11834718Abstract: The present invention relates to methods of determining a cancer treatment prognosis for a subject in need thereof by evaluating epigenetic and genetic changes within a tumor sample from the subject. The present invention further provides methods of treating cancer in a subject by evaluating epigenetic and genetic changes within a tumor sample from the subject. In addition, the present invention provides methods of screening test agents to identify agents that decrease tumor cell plasticity.Type: GrantFiled: September 10, 2020Date of Patent: December 5, 2023Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: Mark Kendell Clement, Gad Getz, Dan-Avi Landau, Alexander Meissner, Catherine Ju-Ying Wu
-
Patent number: 11820978Abstract: The present teachings relate to the extraction of nucleic acid from solid materials. Provided are useful compositions, methods, and kits for obtaining nucleic acids from a solid biological sample or an adhesive material having a biological material adherent or embedded within the adhesive substrate. The extracted nucleic acid can be used in downstream applications such as genotyping, detection, quantification, and identification of the source of the biological material.Type: GrantFiled: January 11, 2021Date of Patent: November 21, 2023Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: James Stray, Jason Yingjie Liu, Maxim Brevnov, Jaiprakash Shewale, Allison Holt
-
Patent number: 11821027Abstract: Provided herein are methods of identifying genomic region(s) predictive of an outcome of treatment with a cell therapy and/or of a phenotype of function of the cells. In some embodiments, the methods include epigenetic and/or epigenomic analyses of the cells in connection with methods for preparing engineered cells for cell therapy and/or predicting response to a cell therapy, e.g., engineered cells for cell therapy. In some embodiments, the methods include steps to assess, characterize and analyze changes or modifications in an epigenetic property of gene region or regions, such as chromatin accessibility, nucleosome occupancy, histone modification, spatial chromosomal conformation, transcription factor occupancy and/or DNA methylation. In some embodiments, the epigenetic and/or epigenomic analysis includes determining the epigenetic properties of a cell, e.g., an engineered cell for cell therapy.Type: GrantFiled: January 10, 2018Date of Patent: November 21, 2023Assignee: Juno Therapeutics, Inc.Inventors: Mark L. Bonyhadi, David G. Kugler, Timothy G. Johnstone, Ronald James Hause, Jr., Lucas J. Thompson, Ryan P. Larson
-
Patent number: 11807848Abstract: Compositions and methods for isolating new variants of known gene sequences are provided. The methods find use in identifying variants, particularly homologs, in complex mixtures. Compositions comprise hybridization baits that hybridize to gene families of interest, particularly agricultural interest, in order to selectively enrich the polynucleotides of interest from complex mixtures. Bait sequences may be specific for a number of genes from distinct gene families of interest and may be designed to cover each gene of interest by at least 2-fold. Thus methods disclosed herein are drawn to an oligonucleotide hybridization gene capture approach for identification of new genes of interest from environmental samples.Type: GrantFiled: January 13, 2021Date of Patent: November 7, 2023Assignee: AgBiome, Inc.Inventors: Vadim Beilinson, Janice Jones, Jessica Parks, Rebecca E. Thayer, Daniel J. Tomso, Scott Joseph Uknes, Sandy Volrath, Eric Russell Ward
-
Patent number: 11795508Abstract: The present invention provides methods for non-invasive determination of sex in a fetus or of Y chromosomal frequency abnormalities—indicative of aneuploidy or sex mosaicisms in a fetus—by detecting and determining the relative contribution genetic sequences from the Y chromosome in view of the percent fetal contribution in a maternal mixed sample.Type: GrantFiled: May 18, 2018Date of Patent: October 24, 2023Assignee: Roche Sequencing Solutions, Inc.Inventors: Craig Struble, Arnold Oliphant, Eric Wang
-
Patent number: 11795510Abstract: The present invention relates to a method of identifying epigenetic reprogramming. Identifying epigenetic reprogramming comprises detecting large organized heterochromatin lysine (K)-9 modified domains (LOCKs) and large DNA hypomethylated blocks in a sample containing DNA from a subject having cancer, for example, PDAC.Type: GrantFiled: October 5, 2017Date of Patent: October 24, 2023Assignees: The Johns Hopkins University, Memorial Sloan Kettering Cancer Center, Vanderbilt UniversityInventors: Oliver McDonald, Xin Li, Christine A. Iacobuzio-Donahue, Andrew P. Feinberg
-
Patent number: 11773443Abstract: The present invention relates to methods to detect an amount of DNA that originates from cells of a given type, where the sample comprising such DNA in admixture with DNA that does not originate from such cells. Such methods are based on differential methylation, at certain regions, of the DNA that originates from the given type of cells compared to the admixed DNA. Such methods have particular application in the detection, from a biological fluid from a pregnant female, of cell free DNA that originates from a foetus or the placenta of a foetus, or the detection, from a biological fluid from an individual, of cell free DNA that originates from cells of a tumour.Type: GrantFiled: June 11, 2018Date of Patent: October 3, 2023Assignee: EUROFINS LIFECODEXX GMBHInventors: Sebastian Gromminger, Wera Hofmann, Hamed Said